All In Biotech

Drug Trial Radar · NCT06531824

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 8,371 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

8,371

Actual

Start

Aug 30, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.

Conditions

  • Kidney Disease, Chronic

Interventions

  • BI 690517Drug

    BI 690517 (called Type M randomized treatment)

  • Placebo matching BI 690517Drug

    Placebo matching BI 690517

  • EmpagliflozinDrug

    Empagliflozin (called Type E)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.Time frame: up to 4 years

Locations

562 sites in 20 countries. Site status is shown where the registry gives one.

  • Apogee Clinical Research

    Huntsville, Alabama

  • Southwest Kidney Institute

    Surprise, Arizona

  • National Heart Institute

    Beverly Hills, California

  • Olive View - UCLA Medical Cente

    Sylmar, California

  • Interventional Cardiology Medical Group

    West Hills, California

  • South Denver Cardiology Associates

    Littleton, Colorado

  • Flourish Research

    Boca Raton, Florida

  • University of Florida Health Shands Hospital

    Gainesville, Florida

  • Florida Kidney Physicians LLC

    Jacksonville Beach, Florida

  • Total Research Group, LLC

    Miami, Florida

  • Bioresearch Partner

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Joseph Maxwell Cleland Atlanta VA Medical Center

    Decatur, Georgia

  • East Coast Institute For Research LLC

    Macon, Georgia

  • Kootenai Research Services

    Coeur d'Alene, Idaho

  • Northwestern University

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Kansas Nephrology Research Institute, LLC

    Wichita, Kansas

  • University of Louisville

    Louisville, Kentucky

  • Medstar Health Research Institute

    Baltimore, Maryland

  • Lake Michigan Nephrology

    Saint Joseph, Michigan

  • St. Clair Nephrology Research, LLC

    Shelby, Michigan

  • Minneapolis VA Health Care System

    Minneapolis, Minnesota

  • Southwest Mississippi Nephrology, Pllc

    Brookhaven, Mississippi

  • Great Plains Nephrology

    North Platte, Nebraska

  • VA Southern Nevada Healthcare System

    North Las Vegas, Nevada

  • Sierra Nevada Specialty Care

    Reno, Nevada

  • Seacoast Kidney and Hypertension Specialists

    Portsmouth, New Hampshire

  • Advanced Heart Care, LLC

    Bridgewater, New Jersey

  • UNM Health Science Center

    Albuquerque, New Mexico

  • VA New York Harbor Healthcare System

    New York, New York

  • Metrolina Nephrology Associates, PA

    Charlotte, North Carolina

  • Metrolina Nephrology Associates, PA

    Charlotte, North Carolina

  • Carolina Kidney Associates

    Greensboro, North Carolina

  • Brookview Hills Research Associates LLC

    Winston-Salem, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Northeast Endocrine Metabolic Associates

    Philadelphia, Pennsylvania

  • Temple University

    Philadelphia, Pennsylvania

  • Clinical Renal Associates

    Upland, Pennsylvania

  • Nephrology Associates, Inc

    East Providence, Rhode Island

Showing 40 of 562 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.